Loading...
XNASPHAR
Market cap616mUSD
Dec 23, Last price  
10.43USD
1D
14.62%
1Q
37.24%
Name

Pharming Group NV

Chart & Performance

D1W1MN
XNAS:PHAR chart
P/E
—
P/S
28.84
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
58.66%
Rev. gr., 5y
9.68%
Revenues
245m
+19.30%
479,681194,0101,006,021924,3531,570,290762,0693,886,98014,035,7609,450,68925,762,43911,838,27816,693,660107,517,335154,575,611189,333,721228,394,666189,853,037205,622,000245,316,000
Net income
-11m
L
000000000000028,589,56740,544,62737,746,00015,996,00013,674,000-10,548,000
CFO
-17m
L
00000000000045,844,23046,186,22774,555,29190,977,07336,125,76722,897,000-17,302,000
Earnings
Mar 12, 2025

Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
URL
https://www.pharming.com/
IPO date
Jul 02, 1998
Employees
332
Domiciled in
NL
Incorporated in
NL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
245,316
19.30%
205,622
8.31%
189,853
-16.88%
Cost of revenue
181,627
201,912
179,408
Unusual Expense (Income)
NOPBT
63,689
3,710
10,445
NOPBT Margin
25.96%
1.80%
5.50%
Operating Taxes
(1,464)
1,313
6,760
Tax Rate
35.39%
64.73%
NOPAT
65,153
2,397
3,684
Net income
(10,548)
-177.14%
13,674
-14.52%
15,996
-57.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,281
4,504
BB yield
-2.98%
-8.29%
Debt
Debt current
5,440
5,233
4,293
Long-term debt
199,228
194,769
178,154
Deferred revenue
Other long-term liabilities
165
Net debt
(19,154)
(17,071)
(19,226)
Cash flow
Cash from operating activities
(17,302)
22,897
36,126
CAPEX
(1,464)
(1,977)
Cash from investing activities
(129,388)
5,323
Cash from financing activities
(941)
(4,982)
FCF
50,235
(4,277)
(22,793)
Balance
Cash
213,424
207,342
191,725
Long term investments
10,398
9,731
9,949
Excess cash
211,556
206,792
192,181
Stockholders' equity
(260,372)
(257,659)
9,445
Invested Capital
650,698
626,892
343,525
ROIC
10.20%
0.49%
1.09%
ROCE
16.32%
1.00%
2.96%
EV
Common stock shares outstanding
657,021
70,714
70,115
Price
1.03
-4.98%
1.08
39.87%
0.78
-39.07%
Market cap
676,731
782.84%
76,654
41.07%
54,339
-37.43%
EV
657,577
59,583
35,113
EBITDA
79,614
16,898
29,166
EV/EBITDA
8.26
3.53
1.20
Interest
5,964
5,358
5,916
Interest/NOPBT
9.36%
144.42%
56.64%